Earnings call transcript: Healwell AI sees 374% revenue surge in Q4 2025

Healwell AI reported Q4 2025 revenue of CAD 32.2M, up 374% YoY, and positive adjusted EBITDA of CAD 1.4M (third consecutive quarter), though IFRS net loss from continuing operations was CAD 7.0M (improved from CAD 11.4M). The company exited Q4 with CAD 18.6M cash, FY2025 revenue of CAD 103.8M (up 427% YoY) driven by Orion Health and other acquisitions, and is targeting >50% organic AI growth and an exit run-rate adjusted EBITDA margin around 10% for 2026. Risks include continued net losses despite positive EBITDA, integration challenges from recent acquisitions, analyst skepticism on near-term profitability, and the stock fell ~1.67% to 0.88 (market cap ~USD/CAD 19.5M).

Analysis

Healwell’s story is now an integration and optionality play more than a pure revenue growth narrative. The strategic combination of enterprise distribution (HIE-style software), proprietary clinical models and a consented clinical data network creates a defensible go-to-market asset — but that defensibility only converts to value if deployments scale into multi-jurisdiction recurring contracts rather than one-off professional services. Expect value realization to be driven by mix shift (recurring/subscription > services), not headline bookings.

Near-term upside is event-driven: successful conversion of pilot AI deployments into multi-year, enterprise rollouts and any liquidity event linked to the company’s private AI stake are binary catalysts that could re-rate the share price quickly. Downside is equally binary — prolonged integration hiccups, payer/provider contract churn, or regulatory friction around data consent could compress multiples quickly because the public float and liquidity profile amplify investor reaction. Timeline: procurement and clinical validation cycles mean material swings will likely play out over quarters (3–12 months), not days.

From competitive dynamics, large cloud and EHR vendors are the natural aggregation threat; they can bundle analytics and data services at scale, compressing future take-rates for smaller platform specialists. Conversely, mid-sized health systems and specialty life-science buyers that prize validated models and consented data are the immediate buyers and pricing power resides with the vendor only after demonstrable, repeatable outcomes. That creates a narrow path to defensible margin expansion — execute integration and prove repeatable economics quickly or risk commoditization.

Key Decisions for Investors

• Speculative, event-driven long on HWAIF (ticker: HWAIF): allocate a small tactical sleeve (0.5–1.0% NAV) via a 9–12 month out-of-the-money call spread or equity with a strict 30–40% stop. Rationale: asymmetric payoff if management converts pilots into enterprise rollouts and if the private AI stake becomes liquid; downside is limited to premium/position size, upside multiple 3x+ if both execution and a liquidity event occur.
• Protection if already long HWAIF: buy 3–6 month puts (HWAIF) sized to cap downside to acceptable loss (e.g., cost of premium ≈ 5–10% of position). Rationale: protects against integration failure, regulatory pushback or a delayed/unrealized monetization event in the next two quarters.
• Diversified, lower-volatility exposure to healthcare AI demand: long Microsoft (MSFT) stock or 12-month call (ticker: MSFT). Rationale: picks up secular platform/cloud tailwinds from healthcare AI deployments without single-company execution risk. Timeframe 6–18 months; expected lower volatility and steady upside as enterprises scale AI workloads.
• Event monetization plan for HWAIF holders: if an announcement signals clear liquidity for the private AI stake (e.g., SpaceX/xAI-related IPO window), scale out 50% of HWAIF holdings at initial pop and tranche remainder at incremental targets (take another 25% at ~2x). Rationale: captures binary upside while locking in proceeds to fund follow-on diligence on recurring revenue momentum.